Get the Stockscreener App
0.7083
3.97%
-0.0293
After Hours:
.7199
0.0116
+1.64%
Gossamer Bio Inc stock is currently priced at $0.7083, with a 24-hour trading volume of 797.47K.
It has seen a -3.97% decreased in the last 24 hours and a -47.53% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7509 pivot point. If it approaches the $0.7037 support level, significant changes may occur.
Previous Close:
$0.7376
Open:
$0.7523
24h Volume:
797.47K
Market Cap:
$159.78M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-0.3205
EPS:
-2.21
Net Cash Flow:
$-159.16M
1W Performance:
-13.62%
1M Performance:
-47.53%
6M Performance:
+48.09%
1Y Performance:
-38.94%
1D Range:
$0.6753
$0.779
52W Range:
$0.4525
$1.88
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
858-684-1300
Address
3013 Science Park Road, Suite 200, San Diego, CA
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Zacks Investment Research
Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
5 Penny Stocks To Buy Now According To Insiders
PennyStocks
Gossamer Bio And 2 Other Stocks Under $1 Insiders Are Buying
Benzinga
Gossamer Bio Inc Stock (GOSS) Financials Data
Gossamer Bio Inc (GOSS) Net Income 2024
GOSS net income (TTM) was -$179.82 million for the quarter ending December 31, 2023, a +21.61% increase year-over-year.
Gossamer Bio Inc (GOSS) Cash Flow 2024
GOSS recorded a free cash flow (TTM) of -$159.16 million for the quarter ending December 31, 2023, a +15.12% increase year-over-year.
Gossamer Bio Inc (GOSS) Earnings per Share 2024
GOSS earnings per share (TTM) was -$1.33 for the quarter ending December 31, 2023, a +51.46% growth year-over-year.
Gossamer Bio Inc Stock (GOSS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Giraudo Bryan | COO/CFO |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,431 |
92,737 |
| Christian Waage | EVP, Tech Ops and Admin |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,430 |
585,934 |
| Peterson Caryn | EVP, Regulatory Affairs |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,343 |
49,833 |
| Aranda Richard | Chief Medical Officer |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,342 |
198,799 |
| Milligan Sandra | Director |
Nov 15 '23 |
Buy |
0.79 |
32,000 |
25,213 |
32,000 |
| Giraudo Bryan | COO/CFO |
Nov 13 '23 |
Buy |
0.56 |
200,000 |
112,880 |
380,010 |
| Aranda Richard | Chief Medical Officer |
Jun 22 '23 |
Sale |
1.29 |
1,814 |
2,340 |
197,574 |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
3.69%
0.93%
Cap:
|
Volume (24h):